面向犬猫的皮下植入式无源LC甘油三酯监测芯片 三联酶级联 丝素蛋白水凝胶敏感膜 射频耦合
无源LC谐振式传感器的器件结构与耦合敏感机理(含植入/体内与介电型检测)
共同点是围绕无电池电感-电容谐振回路的器件本体展开:硅基无线无源LC微系统、IDE(叉指电极)型LC器件、微加工眼内压植入传感器、无线无源器件设计与特性分析,以及微凝胶介电型体内连续检测。这一组提供"线圈-电容-谐振频率"的转换模型、微创/植入封装形态与介电(而非电化学)敏感通道选择,是芯片本体结构与体内敏感界面的直接原型参考。
- Silicon-Based Wireless Passive LC Microsystems with Potential for Pulmonary Artery Pressure Monitoring(Pichao Pan, Li Wang, Min Liu, Xin-Xin Li, 2025, IEEE/LEOS International Conference on Optical MEMS)
- Evaluation of a Wireless IDE-Based LC Resonant Sensor for Monitoring Biliary Stent Occlusion(Hyeon-su Kim, Dong-Su Kim, Changsin Park, Young Baek Kim, Dong-Weon Lee, 2026, Journal of Sensor Science and Technology)
- Wireless Intraocular Pressure Sensing Using Microfabricated Minimally Invasive Flexible-Coiled LC Sensor Implant(Po-Jui Chen, Saloomeh Saati, R. Varma, M. Humayun, Yu-Chong Tai, 2010, Journal of microelectromechanical systems)
- Microgels-based In Vivo Biosensor for Continuous Blood Glucose Monitoring(Z. Gong, Xiang Chen, Muhammad Ali, Shanaz X. Chen, Yi-Fan Chen, 2024, Annual International Conference of the IEEE Engineering in Medicine and Biology Society)
- Design and Characteristics of a Wireless Non-enzyme Glucose Sensor Based on Resonant LC Passive Circuit(T. Pham, P. Nguyễn, Anh Van Bui, 2024, VNU Journal of Science Mathematics - Physics)
高灵敏柔性无源LC压力、应变与湿度传感器的敏感电容结构与灵敏度提升
共同点是以柔性/薄膜/球形等结构创新和离子电子(iontronic)电容增强来提高LC传感器灵敏度与线性度,覆盖压力、应变、湿度、薄膜平面型等多种被测量与结构(含超高压敏、双机制柔性压力与高灵敏柔性应变)。其灵敏度、Q值、耦合距离与重复性数据,为芯片"谐振频移—浓度/压力"标定曲线与敏感膜叠层设计提供定量设计依据。
- A Wireless Passive LC Flexible Strain Sensor Utilizing a Curved-Beam Interdigital Capacitor(Chen Li, Ya-Qi Shi, Rui Yang, Zi-Hao Li, Yu-Liang Fan, Miao-Miao Zheng, Yu Zhang, Jing Miao, Bo-Shan Sun, 2026, IEEE Sensors Journal)
- Wireless Passive Ultrahigh Sensitivity LC Pressure Sensor Based on Ionic Dielectric Layer for Wearable Electronics(Hai-Rong Kou, Yuzhen Wang, Yu-Hang Pang, Yu-Lei Chen, Li-Bo Yang, Xiao-Yong Zhang, Zhen-Zhen Shang, Liang Zhang, Zhi-Guo Gui, 2025, IEEE Sensors Journal)
- High-sensitivity flexible wireless passive LC pressure sensor enabled by a magnetic field-induced ciliary microstructure(Hang-Liang Ren, Yi Hu, Qian-Cheng Xu, Jun-Hao Meng, Xiang-Jun Jin, Zhi-Ping Sun, Zhen-Yu Xue, Pei-Mei Dong, Ke Wang, Xu-Dong Cheng, 2026, Smart materials and structures (Print))
- High-sensitivity LC wireless passive flexible pressure sensor based on anisotropically distributed nmFe with dual-sensitivity mechanism(Hang-Liang Ren, Xiaofeng Zheng, Yun-Long Zhu, Zhi-Cheng Dong, Yi Hu, Qian-Cheng Xu, Jian Li, Zhen-Yu Xue, Pei-Mei Dong, Ke Wang, Xu-Dong Cheng, 2025, Measurement science and technology)
- Highly sensitive flexible wireless passive LC temperature sensor with dual-sensitive units for bearing monitoring(Xu-Dong Cheng, Yi Hu, Jingyi Tu, Xiaofeng Zheng, Zhi-Cheng Dong, Qian-Cheng Xu, Yun-Long Zhu, Jian Li, Hang-Liang Ren, Ruiwenxuan Wang, Zhen-Yu Xue, Ke Wang, Pei-Mei Dong, 2026, Sensors and Actuators A-Physical)
- Passive Spherical Capacitive-Based Resonant Sensor for Wireless Soil Moisture Monitoring(Sheng Ding, Qiwu Zhang, S. Roundy, Le-Ang K. Kam, C. Zesiger, D. Young, 2025, Italian National Conference on Sensors)
- Iontronic capacitance-enhanced LC wireless passive pressure sensor for high-performance flexible sensing(Ke Liu, Yuxin Qin, Guirong Wu, Daren Wang, Haiyan Zhang, Weidong Wang, Yang-Bo Yuan, Li-Bo Gao, 2023, Applied Physics Letters)
- Study on LC wireless passive humidity sensor using MoS2/CS composite material: examination of high sensitivity and the chemical-physical synergistic adsorption mechanism(Jiang-Rong Hou, Liang Guo, Bingzhi Yan, Shu-Xian Gao, Chu-Xiao Sun, Yan-Pei Xu, Qi Wang, 2025, Measurement)
- Novel Planar Passive Wireless Thin Film LC Temperature Sensor(K. Rivera, 2024, IEEE Sensors Letters)
多参数、双敏感元件与频率可调谐LC谐振结构设计
共同点是解决无源单谐振回路的"单参数、难区分、不可调"缺陷:双LC谐振电路、双敏感元件结构、频率可调谐LC谐振器、压力-温度双参数无线无源传感及多种新型谐振结构。该组为芯片在皮下同时校正温度漂移、区分基线与环境干扰、实现多路复用读出提供结构层面的解决方案,直接对应长期在体测量的抗漂移需求。
- A dual LC resonant circuit integrated wireless passive force and temperature sensor for harsh-environment applications(Hai-Rong Kou, Li-Bo Yang, Xiao-Yong Zhang, Zhen-Zhen Shang, Jun Shi, Xiao-Long Wang, 2022, AIP Advances)
- A dual-sensitive element wireless passive LC temperature sensor and application in bearing monitoring(Zhi-Cheng Dong, Jingyi Tu, Qian-Cheng Xu, Yun-Long Zhu, Jian Li, Yi Hu, Hang-Liang Ren, Pei-Mei Dong, Xu-Dong Cheng, Zhen-Yu Xue, 2025, Measurement science and technology)
- A Frequency-Tunable LC Resonant Wireless Passive Temperature Sensor(Xindi An, Jiongzheng Zhang, T.-E. Shen, Qi Wen, Yu-Jian Jin, Jun-Yang Li, 2026, IEEE International Conference on Nano/Micro Engineered and Molecular Systems)
- A Wireless Passive Pressure and Temperature Sensor via a Dual LC Resonant Circuit in Harsh Environments(Qiu-lin Tan, Tao Luo, Tanyong Wei, Jun Liu, Li-Wei Lin, J. Xiong, 2017, Journal of microelectromechanical systems)
- A Novel-Structure LC Resonant Passive Wireless Sensor for NO2 Sensing(Zhiyang Liu, Yan-Bai Shen, Sikai Zhao, Jin-Zhou Bai, Rui-Xue Ma, Shu-Ling Gao, Wen-Gang Liu, Qiang Zhao, 2023, Chemosensors)
- A Wireless Passive LC Resonant Sensor Based on LTCC under High-Temperature/Pressure Environments(L. Qin, Dandan Shen, Tanyong Wei, Qiu-lin Tan, Tao Luo, Zhaoying Zhou, J. Xiong, 2015, Italian National Conference on Sensors)
射频耦合供能、读出电路与耦合系数/谐振频率解调算法
共同点聚焦"外部阅读器如何隔空供能并准确读出频移":RF MEMS传感器驱动/读出SoC、集成无源器件与谐振感应耦合(含负载隔离的无线供电与数据回传)、电感耦合注入锁定振荡器的锁定区间与相位噪声分析、以及耦合系数与接收端谐振频率的超快辨识算法。该组为皮下弱耦合、小尺寸线圈条件下的供能效率、测量线性度与频移解算误差控制提供电路与算法依据。
- An RF MEMS Sensor Driver/Readout SoC with Resonant Frequency Shift and Closed-Loop Envelope Regulation for Microplastic Detection(Seung-Beom Ku, Kwonhong Lee, Han-Sol Lee, Kyeongho Eom, Minju Park, Jinhyoung Kim, Cheolung Cha, Hyung-Min Lee, 2023, European Solid-State Circuits Conference)
- An RF MEMS Sensor Driver/Readout SoC With Resonant Frequency Shift and Closed-Loop Envelope Regulation for Portable Microplastic Detection(Seung-Beom Ku, Jinhyoung Kim, Kwonhong Lee, Han-Sol Lee, Kyeongho Eom, Minju Park, Cheolung Cha, Hyung-Min Lee, 2025, IEEE Journal of Solid-State Circuits)
- Analysis of Inductively Injection Locked Oscillators at an Integer Frequency Ratio(F. Ramírez, R. Melville, A. Súarez, 2022, European Microwave Conference)
- An Ultrafast Estimation Method for Coupling Coefficient and Receiver Resonant Frequency in Universal Wireless Power Transfer Systems(Jun-Ming Zeng, Yun Yang, Ke-Rui Li, Shuxin Chen, S. Hui, 2024, IEEE transactions on power electronics)
- Integrated passives and resonant inductive coupling as a displacement sensing mechanism for large piston/rotation micromirrors(Victor Farm-Guoo Tseng, 2015, No journal)
- A Wireless Power and Data Transfer System for Medical Implants Using a Miniaturized Inductive Link With Frequency-Splitting Enhancement(Yechan Park, Hung Dang Phan, Donghyun Youn, Daehyeon Kwon, Chul Kim, M. Je, 2025, IEEE Journal of Solid-State Circuits)
CardioMEMS无源植入血流动力学监测的临床验证与卫生经济学证据
共同点是以CardioMEMS肺动脉压无源植入传感器为标杆的完整证据链:CHAMPION/GUIDE-HF/MONITOR-HF、COAST与MEMS-HF等多中心前瞻性及上市后注册研究、90天早期结局、单中心实施经验、特殊人群(LVAD、妊娠期心衰)安全植入个案、最新循证综述与欧洲体系下的成本效果分析。该组证明"无电池、微创植入、遥测读取、长期免维护、按数据提前干预"路径安全有效且具经济性,为犬猫皮下植入芯片的植入方式、随访范式与准入/支付逻辑提供直接对标。
- Heart Failure Hospitalisation Reduction With Remote Pulmonary Artery Pressure Monitoring in Australia: Results of the CardioMEMS HF System OUS Post-Market Study(S. McKenzie, S. Pavia, D. O'Donnell, C. Gazzola, P. Adamson, 2024, Heart, Lung and Circulation)
- Cost‐effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS‐HF system) in chronic heart failure in the Netherlands(H. Mokri, P. Clephas, R. D. de Boer, P. van Baal, J. Brugts, M. Rutten-van Mölken, 2024, European Journal of Heart Failure)
- Implantable Device-Guided Pulmonary Artery Pressure Monitoring Reduces Heart Failure Readmissions(Abdelrahman A. Zaied, Kirby Brown, S. Dunlap, B. Meyer, Ashley Wehr, Isha Darshane, Vishal Arora, 2025, JACC Case Reports)
- Heart failure hospitalization reduction and long-term safety with remote pulmonary artery pressure monitoring: results of the CardioMEMS HF System OUS Post-Market Study(F. Roubille, S. McKenzie, A. Flett, P. Folley, K. Rossing, M. Ciccarelli, A. Pouleur, C. Gazzola, E. Park, P. Adamson, P. de Groote, 2024, European Heart Journal)
- Heart failure hospitalization reduction and long-term safety with remote pulmonary artery pressure monitoring: results of the CardioMEMS heart failure system outside United States (of America) post-market study(P. de Groote, S. McKenzie, A. Flett, P. Foley, K. Rossing, M. Ciccarelli, A. Pouleur, C. Gazzola, Eunyoung Park, F. Roubille, 2026, European Heart Journal Open)
- Clinical Update of the Latest Evidence for CardioMEMS Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Promising System for Remote Heart Failure Care(J. Brugts, S. Radhoe, Dilan Aydin, D. Theuns, J. Veenis, 2021, Italian National Conference on Sensors)
- Effectiveness of Pulmonary Artery Pressure Monitoring with CardioMEMS in Patients with Heart Failure on Dialysis(K. Labagnara, Prashant N. Bhenswala, P. Mendapara, J. Hirsch, K. Stawiarski, K. Jhaveri, 2026, Journal of the American Society of Nephrology)
- Pulmonary artery pressure‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF)(C. Angermann, B. Assmus, S. Anker, F. Asselbergs, J. Brachmann, Marie-Elena Brett, J. Brugts, G. Ertl, G. Ginn, L. Hilker, Friedrich Koehler, S. Rosenkranz, Qian Zhou, P. Adamson, M. Böhm, 2020, European Journal of Heart Failure)
- CRT-300.11 90 -Day Outcomes of Pulmonary Artery Pressure Monitoring Device (CardioMEMS)(B. Hussain, A. Mahmood, Rahul Vasudev, T. Alexander, A. Kassier, 2023, JACC: Cardiovascular Interventions)
- 90-Day Outcomes of Pulmonary Artery Pressure Monitoring Device (CardioMEMS)(B. Hussain, Ahmed M. Mahmood, Rahul Vasudev, T. Alexander, A. Kassier, 2023, Cardiovascular Revascularization Medicine)
- An update on the CardioMEMS pulmonary artery pressure sensor(P. Ayyadurai, H. Alkhawam, Muhammad Saad, M. Al-Sadawi, Niel N. Shah, C. E. Kosmas, T. Vittorio, 2019, Therapeutic Advances in Cardiovascular Disease)
- Safety and feasibility of hemodynamic pulmonary artery pressure monitoring using the CardioMEMS device in LVAD management(J. Veenis, S. Radhoe, Nicolas M. Mieghem, O. Manintveld, J. Bekkers, K. Çalışkan, A. Bogers, F. Zijlstra, J. Brugts, 2021, Journal of cardiac surgery)
- Abstract 15019: Safe Implantation of Remote Pulmonary Artery Pressure Monitoring System (CARDIOMEMS) in a Pregnant Patient With Severe Heart Failure(Javaria Ahmad, Hajra Awwab, Brittin Thibodeaux, Lillian Faucheaux, Danielle B. Cooper, P. Barrilleaux, D. Lewis, P. Dominic, 2022, Circulation)
皮下/半植入式连续生化监测器件的结构形态、生物相容天线与长期在体稳定性
共同点回答"埋进皮下后能否长期测得准":可注射/针状/全植入器件的结构形态筛选、TiN等生物相容性皮下天线、可见光驱动长期稳定纳米光子传感、GOx/AuNP/PEDOT修饰电极的连续测量与ISO 10993验证、电磁式皮下植入传感器在猪与比格犬上的血糖跟踪、Eversense全皮下CGM与CGM技术路线综述、皮肤界面与组织液—器件扩散动力学,以及多路微针电极阵列的自校准策略。该组为芯片微创注射尺寸、封装与天线布置、酶活衰减与信号漂移校正、动物在体验证方案提供工程化对照。
- Design selection of a fully-implantable and optically-transduced glucose biosensor via Monte Carlo modeling(Jesse Fine, M. Mcshane, Gerard L. Coté, 2021, No journal)
- Biocompatible Antennas for Implantable Biosensor Systems(Ryan B. Green, E. Topsakal, 2019, International workshop on Antenna Technology: Small and Smart Antennas Metamaterials and Applications)
- Visible-Light Driven Implantable Nanophotonic Biosensor for Continuous Glucose Monitoring via Metalloporphyrin Q-Band Modulation and Enzymatic Cascade Stabilization.(Xinyu Wang, Zhu-Li Wu, Shuangyun Bai, Shihe Shao, Bing Liu, Chang-Feng Wu, Kai Sun, 2026, ACS Sensors)
- Fabrication of a biocompatible and continuous glucose biosensor with the poly(3,4-ethylenedioxythiophene) modified electrode(Jiansin Li, Xiang Bi, S. Tamulevičius, D. Erts, Chiung-Fen Chang, Ye-Song Gu, 2019, Journal of the Taiwan Institute of Chemical Engineers / Elsevier)
- Semi-implantable polyimide/PTFE needle-shaped biosensor for continuous glucose monitoring(Hyosang Yoon, Sungkwan Jeong, X. Xuan, J. Park, 2017, International Conference on Solid-State Sensors, Actuators and Microsystems)
- Needle-implantable, wireless biosensor for continuous glucose monitoring(Santhisagar Vaddiraju, M. Kastellorizios, A. Legassey, D. Burgess, F. Jain, F. Papadimitrakopoulos, 2015, International Conference on Wearable and Implantable Body Sensor Networks)
- Continuous Interstitial Glucose Monitoring through a Long-Term Subcutaneous Implantable Sensor during Pregnancy in Type 1 Diabetes: A Two-Patient Case Report(Betella Nazarena, Resi Veronica, A. Gaglio, Ciafardini Antea, F. Mazzoleni, Vena Walter, E. Orsi, Bossi Antonio Carlo, 2025, Endocrine, Metabolic & Immune Disorders - Drug Targets)
- Experts opinion: implantable continuous glucose monitoring system — innovation in the management of diabetes(A. Szadkowska, D. Zozulińska-Ziółkiewicz, M. Walczak, K. Cyganek, B. Wolnik, Andrzej Gawrecki, M. Myśliwiec, 2020, Clinical Diabetology)
- Review of the Long-Term Implantable Senseonics Continuous Glucose Monitoring System and Other Continuous Glucose Monitoring Systems(J. Joseph, 2020, Journal of Diabetes Science and Technology)
- Self-calibrating multiplexed microneedle electrode array for continuous mapping of subcutaneous multi-analytes in diabetes(Xiang-Ling Li, Shantao Zheng, Mengyi He, Xin-Shuo Huang, Cheng Yang, Jing-Shan Mo, Jing-Bo Yang, Cheng-Duan Yang, Hui-jiuan Chen, Xi Xie, 2025, The Innovation)
- Subcutaneously implantable electromagnetic biosensor system for continuous glucose monitoring(Seongmun Kim, Jagannath Malik, J. Seo, Y. Cho, F. Bien, 2022, Scientific Reports)
- Impact on diabetes control and patient-reported outcomes of a newer implantable continuous glucose monitoring system (Eversense® CGM System): a single-centre retro- and prospective observational study.(Dimitri Guy Rohner, Lukáš Burget, C. Henzen, S. Fischli, 2024, Swiss medical weekly)
- Continuous glucose monitoring systems - Current status and future perspectives of the flagship technologies in biosensor research.(Inyoung Lee, David Probst, D. Klonoff, K. Sode, 2021, Biosensors & bioelectronics)
- Opportunities at the skin interface for continuous patient monitoring: a development model based on lactate and glucose(P. Connolly, C. Cotton, F. Morin, 2002, Proceedings of the IEEE-EMBS Special Topic Conference on Molecular, Cellular and Tissue Engineering)
脂肪酶-甘油激酶-G3PO三联酶级联甘油三酯安培型传感器的构建与性能
共同点是以Lipase/GK/G3PO(部分加HRP)级联为核心识别机制构建甘油三酯传感器,并以酶纳米颗粒、氧化石墨烯、Au/PEDOT-PSS/PEDOT修饰丝网印刷或铅笔石墨、一次性电极等不同换能界面实现电流检测,系统给出线性范围、检出限、响应时间与真实血清相关性。该组是敏感膜反应路径、级联配比、输出信号—甘油三酯浓度换算关系与抗干扰性能的直接实验依据。
- An improved amperometric triglyceride biosensor based on co-immobilization of nanoparticles of lipase, glycerol kinase and glycerol 3-phosphate oxidase onto pencil graphite electrode.(Vinay Narwal, C. Pundir, 2017, Enzyme and Microbial Technology)
- An Enhanced Amperometric Triglyceride Biosensor by Graphene Oxide Nanoparticles(C. S. Pundir, Vinay Narwal, Parveen Kumar, Deepa, 2025, International Journal of Applied Sciences and Biotechnology)
- Amperometric biosensor based on poly (3,4-ethylenedioxythiophene) / poly(styrenesulfonate) / gold nanocomposite modified screen-printed carbon electrode for triglyceride determination(Angkana Phongphut, No journal)
- Construction of triglyceride biosensor based on nickel oxide-chitosan/zinc oxide/zinc hexacyanoferrate film.(J. Narang, N. Chauhan, C. Pundir, 2013, International Journal of Biological Macromolecules)
- Fabrication of an Amperometric Triglyceride Biosensor based on PVC Membrane(J. Narang, Minakshi, M. Bhambi, C. Pundir, 2009, Analytical Letters)
- Construction of a triglyceride amperometric biosensor based on chitosan-ZnO nanocomposite film.(J. Narang, C. Pundir, 2011, International Journal of Biological Macromolecules)
- Construction of an amperometric triglyceride biosensor using PVA membrane bound enzymes.(C. Pundir, Bharvi Sandeep Singh, J. Narang, 2010, Clinical Biochemistry)
- Construction of an amperometric TG biosensor based on AuPPy nanocomposite and poly (indole-5-carboxylic acid) modified Au electrode(J. Narang, N. Chauhan, P. Rani, C. Pundir, 2013, Bioprocess and biosystems engineering (Print))
- Amperometric triglyceride bionanosensor based on nanoparticles of lipase, glycerol kinase, glycerol-3-phosphate oxidase.(C. Pundir, V. Aggarwal, 2017, Analytical Biochemistry)
- A disposable amperometric biosensor based on inkjet-printed Au/PEDOT-PSS nanocomposite for triglyceride determination(Angkana Phongphut, C. Sriprachuabwong, A. Wisitsoraat, A. Tuantranont, S. Prichanont, P. Sritongkham, 2013, Sensors and Actuators B-chemical)
- A new multienzyme-type biosensor for triglyceride determination(A. Yücel, H. M. Özcan, A. Sağıroğlu, 2016, Preparative Biochemistry & Biotechnology)
- Bioelectrocatalytic sensor for triglycerides in human skin sebum based on enzymatic cascade reaction of lipase, glycerol kinase and glycerophosphate oxidase.(Chi Yong Jeong, Yong D. Han, Jae Ho Yoon, H. Yoon, 2014, Journal of Biotechnology)
甘油三酯酶法测定原理与经典酶电极/氧电极换能体系
共同点是从分析化学源头给出甘油三酯的酶水解-甘油-磷酸氧化测量原理与经典换能方式:血清甘油三酯的酶法测定与基于脂肪酶的血清甘油三酯测定、安培型酶传感器的构建方法学、以及以氧电极为换能基础的生物传感器制备。该组为芯片选定G3PO氧化产生H2O2/O2消耗这一可电学读取的信号通道、以及校准与参考方法(医院生化仪)一致性验证提供原理与标准化参照。
- Determination of serum triglyceride by enzyme electrode using covalently immobilized enzyme on egg shell membrane.(J. Narang, Minakshi, M. Bhambi, C. Pundir, 2010, International Journal of Biological Macromolecules)
- Determination of serum triglycerides using lipase, glycerol kinase, glycerol-3-phosphate oxidase and peroxidase co-immobilized onto alkylamine glass beads.(V. Kalia, C. Pundir, 2004, Indian Journal of Biochemistry & Biophysics)
- Construction of an amperometric enzymic sensor for triglyceride determination(C. Pundir, 2008, Sensors and Actuators B-chemical)
- Preparation of Oxygen Meter Based Biosensor for Determination of Triglyceride in Serum(M. Bhambi, C. Pundir, 2006, No journal)
多酶共固定化与丝素蛋白水凝胶/纳米复合基质的稳定化策略
共同点聚焦"酶怎样被固定并长期保持活性与级联效率":脂肪酶与甘油激酶的戊二醛共价偶联及多酶共固定化(含可重复使用酶条)、丝素蛋白盐驱动自组装无交联剂多酶共包埋、机械研磨丝素纳米纤维固定化、丝素蛋白作为可吸收生物相容性酶固定基质、丝素水凝胶封装 graphene FET、石墨烯-水凝胶杂化与纳米颗粒平台的理性设计,并配合组织液—水凝胶内底物扩散动力学分析。该组直接支撑本项目"丝素蛋白水凝胶作敏感膜基质+三酶共固定"的选材、级联配比调控、抗蛋白吸附与在体寿命论证。
- Covalent immobilization of lipase, glycerol kinase, glycerol-3-phosphate oxidase & horseradish peroxidase onto plasticized polyvinyl chloride (PVC) strip & its application in serum triglyceride determination(N. Chauhan, J. Narang, C. Pundir, 2014, The Indian journal of medical research)
- Co-immobilization of lipase, glycerol kinase, glycerol-3-phosphate oxidase and peroxidase onto alkylamine glass beads through glutaraldehyde coupling.(V. Kalia, C. Pundir, 2002, Indian Journal of Biochemistry & Biophysics)
- Co-immobilization of lipase, glycerol kinase, glycerol-3-phosphate oxidase and peroxidase on to aryl amine glass beads affixed on plastic strip for determination of triglycerides in serum.(Minakshi, C. Pundir, 2008, Indian Journal of Biochemistry & Biophysics)
- Salt‐Driven Silk Fibroin Assembly for Solvent‐Free Multienzyme Co‐Immobilization(Juan Cruz Almada, Miguel Marco‐Martín, Uriel A. Ruiz-Castillo, Susana Velasco-Lozano, 2026, ChemCatChem)
- Immobilization of laccases on mechanically ground silk fibroin nanofibers for enhanced stability.(Ayari Miyawaki, S. Sakai, 2024, International Journal of Biological Macromolecules)
- A comparative study of graphene-hydrogel hybrid bionanocomposites for biosensing.(S. Burrs, D. Vanegas, Y. Rong, M. Bhargava, N. Mechulan, P. Hendershot, H. Yamaguchi, C. Gomes, E. Mclamore, 2015, In Analysis)
- Rational Design of Nanoparticle Platforms for "Cutting-the-Fat": Covalent Immobilization of Lipase, Glycerol Kinase, and Glycerol-3-Phosphate Oxidase on Metal Nanoparticles.(V. Aggarwal, C. Pundir, 2016, Methods in Enzymology)
- On the Molecular Diffusion Dynamics Between Subcutaneous Tissue and Microneedles for Wearable Continuous Glucose Monitoring(Wensheng Lin, Bin-Bin Cui, Xuecheng He, Suo Tu, Shi-Lei Dai, Xinran Zhang, Ivo Pang, Xiao-Nan Chen, Ji-Xiang Zhu, Shi-Ming Zhang, 2026, Advanced NanoBiomed Research)
- Silk‐Fibroin as Biocompatible and Bioresorbable Enzyme Immobilization Matrix for Screen‐Printed Amperometric Glucose Biosensors(K. Janus, Stefan Achtsnicht, B. Isella, A. Kopp, K. Miyamoto, T. Yoshinobu, M. Keusgen, M. Schöning, 2025, Advanced Sensor Research)
- Silk fibroin hydrogel encapsulated graphene filed-effect transistors as enzyme-based biosensors(Zhaoliang Wang, Hai-Yang Yu, Zheng Zhao, 2021, Microchemical Journal)
- Silk Fibroin Nanofiber–Immobilized Horseradish Peroxidase Enables Continuous Preparation of Injectable Hydrogels With Negligible Residual Enzyme for Drug Delivery(Ayari Miyawaki, S. Sakai, 2026, Advanced Materials & Technologies)
犬猫肥胖与高脂血症的流行病学、继发危害与临床干预管理
共同点提供伴侣动物血脂代谢紊乱的临床痛点与市场需求证据:犬肥胖/超重的患病率与关联因素调查、猫肥胖与高脂血症从发病机制到预防的综述(慢性低度炎症、胰岛素抵抗、继发糖尿病与心肌病)、犬原发性/继发性高脂血症的病因构成与贝扎贝特治疗转归、高脂血症相关疾病与体况/体型指标的相关性、猫继发性高甘油三酯血症的病因与贝特类疗效安全性,以及兽医科诊疗模式变化的时代背景研究。该组支撑"老年犬猫早期无症状、需反复抽血、继发胰腺炎/肾病/糖尿病"的监测缺口与提前干预价值论证。
- Establishing diagnostic criteria for feline obesity using a highly sensitive serum amyloid A assay(Miki Kobayashi, M. Kobayashi, Tomoaki Hirose, M. Yuki, Satoru Imano, Yukari Asahi, Takahiro Teshima, T. Arai, 2025, Frontiers in Veterinary Science)
- Prevalence of canine obesity in the city of São Paulo, Brazil(M. Porsani, F. Alves Teixeira, Vinícius Oliveira, Vivian Pedrinelli, R. Dias, A. German, M. Brunetto, 2020, Scientific Reports)
- From pathogenesis to prevention: an update on the management of obesity and its associated comorbidities in cats(Hua-Kai Wang, Wei-Wei Wang, Yu-Qiang Zhang, Jia-Hang Yao, Yi-Ran Liu, Li Pan, Ran Wang, Jianmei Wang, Zhao-Fei Xia, Li-Shui Chen, Wei Xiong, 2026, Frontiers in Veterinary Science)
- Therapy of Canine Hyperlipidemia with Bezafibrate(V. de Marco, K. Noronha, T. C. Casado, E. Nakandakare, J. Flório, E. Z. Santos, C. Gilor, 2017, Journal of Veterinary Internal Medicine)
- Correlation Between Hyperlipidemia-Related Diseases and Thorax/Thigh Circumference Ratio Along with Body Condition Score in Dogs Focusing on Molecular Mechanism: A Pilot Study and Literature Review(Kyuhyung Choi, 2024, Life)
- Therapy for feline secondary hypertriglyceridemia with fenofibrate(D. Miceli, J. Guevara, S. Ferraris, O. Pignataro, M. Gallelli, 2022, Journal of feline medicine and surgery)
- 200.04 Impact of COVID-19 Era on Pulmonary Artery Pressure Monitoring Device (CardioMEMS) Readmissions(B. Hussain, A. Mahmood, K. Dahal, A. Kanmanthareddy, T. Alexander, A. Kassier, 2024, JACC: Cardiovascular Interventions)
合并三套初始化分组后,将全部87篇文献(三组各29篇,彼此不重复)按项目技术主线重排为十个相互并列的板块,形成"器件原理—多参数结构—射频读出—临床标杆—在体落地—酶识别—换能方法学—膜材料固定—动物临床需求"的完整证据链。其中:第1—3组刻画无源LC器件从基础结构(硅基/IDE/微加工植入/介电型体内传感)到高灵敏柔性压力应变湿度敏感结构、再到双敏感/可调谐多参数谐振结构的设计谱系,对应芯片"无电池+频移读出+抗温漂多参数"的本体需求;第4组补齐射频耦合供能、读出SoC与耦合系数/频率解调算法,解决皮下弱耦合下的供能与精度问题;第5组以CardioMEMS十三篇多中心与注册研究及成本效果分析证明无源植入连续监测可落地且经济;第6组以可注射/针状CGM、Eversense、皮下天线与组织液扩散、自校准微针阵列等十四篇回答植入形态、生物相容与长期漂移校正;第7组十二篇集中呈现Lipase/GK/G3PO三联酶级联安培型甘油三酯传感器的构建与关键性能参数,第8组四篇回溯酶法测定与氧电极/酶电极换能原理作为信号通道与参考方法依据;第9组十一篇聚焦多酶共固定化与丝素蛋白水凝胶、丝素纳米纤维、石墨烯-水凝胶等基质稳定化及底物扩散-反应动力学,直接支撑敏感膜选材与寿命论证;第10组七篇提供犬猫肥胖与高脂血症的患病率、继发危害(胰腺炎、肾病、糖尿病)与贝特类干预证据,确立居家长期血脂预警的临床痛点与市场价值。整体分组互不交叉,主题具体,覆盖了初始分组中的全部文献,并明确保留并强化了"多酶共固定化基质""酶法/换能方法学""多参数抗漂移LC结构"等易被笼统合并的独立论点。
共同点是围绕无电池电感-电容谐振回路的器件本体展开:硅基无线无源LC微系统、IDE(叉指电极)型LC器件、微加工眼内压植入传感器、无线无源器件设计与特性分析,以及微凝胶介电型体内连续检测。这一组提供"线圈-电容-谐振频率"的转换模型、微创/植入封装形态与介电(而非电化学)敏感通道选择,是芯片本体结构与体内敏感界面的直接原型参考。相关文献:Pichao Pan et. al, 2025 等 5 篇文献
共同点是以柔性/薄膜/球形等结构创新和离子电子(iontronic)电容增强来提高LC传感器灵敏度与线性度,覆盖压力、应变、湿度、薄膜平面型等多种被测量与结构(含超高压敏、双机制柔性压力与高灵敏柔性应变)。其灵敏度、Q值、耦合距离与重复性数据,为芯片"谐振频移—浓度/压力"标定曲线与敏感膜叠层设计提供定量设计依据。相关文献:Chen Li et. al, 2026 等 9 篇文献
共同点是解决无源单谐振回路的"单参数、难区分、不可调"缺陷:双LC谐振电路、双敏感元件结构、频率可调谐LC谐振器、压力-温度双参数无线无源传感及多种新型谐振结构。该组为芯片在皮下同时校正温度漂移、区分基线与环境干扰、实现多路复用读出提供结构层面的解决方案,直接对应长期在体测量的抗漂移需求。相关文献:Hai-Rong Kou et. al, 2022 等 6 篇文献
共同点聚焦"外部阅读器如何隔空供能并准确读出频移":RF MEMS传感器驱动/读出SoC、集成无源器件与谐振感应耦合(含负载隔离的无线供电与数据回传)、电感耦合注入锁定振荡器的锁定区间与相位噪声分析、以及耦合系数与接收端谐振频率的超快辨识算法。该组为皮下弱耦合、小尺寸线圈条件下的供能效率、测量线性度与频移解算误差控制提供电路与算法依据。相关文献:Seung-Beom Ku et. al, 2023 等 6 篇文献
共同点是以CardioMEMS肺动脉压无源植入传感器为标杆的完整证据链:CHAMPION/GUIDE-HF/MONITOR-HF、COAST与MEMS-HF等多中心前瞻性及上市后注册研究、90天早期结局、单中心实施经验、特殊人群(LVAD、妊娠期心衰)安全植入个案、最新循证综述与欧洲体系下的成本效果分析。该组证明"无电池、微创植入、遥测读取、长期免维护、按数据提前干预"路径安全有效且具经济性,为犬猫皮下植入芯片的植入方式、随访范式与准入/支付逻辑提供直接对标。相关文献:S. McKenzie et. al, 2024 等 13 篇文献
共同点回答"埋进皮下后能否长期测得准":可注射/针状/全植入器件的结构形态筛选、TiN等生物相容性皮下天线、可见光驱动长期稳定纳米光子传感、GOx/AuNP/PEDOT修饰电极的连续测量与ISO 10993验证、电磁式皮下植入传感器在猪与比格犬上的血糖跟踪、Eversense全皮下CGM与CGM技术路线综述、皮肤界面与组织液—器件扩散动力学,以及多路微针电极阵列的自校准策略。该组为芯片微创注射尺寸、封装与天线布置、酶活衰减与信号漂移校正、动物在体验证方案提供工程化对照。相关文献:Jesse Fine et. al, 2021 等 14 篇文献
共同点是以Lipase/GK/G3PO(部分加HRP)级联为核心识别机制构建甘油三酯传感器,并以酶纳米颗粒、氧化石墨烯、Au/PEDOT-PSS/PEDOT修饰丝网印刷或铅笔石墨、一次性电极等不同换能界面实现电流检测,系统给出线性范围、检出限、响应时间与真实血清相关性。该组是敏感膜反应路径、级联配比、输出信号—甘油三酯浓度换算关系与抗干扰性能的直接实验依据。相关文献:Vinay Narwal et. al, 2017 等 12 篇文献
共同点是从分析化学源头给出甘油三酯的酶水解-甘油-磷酸氧化测量原理与经典换能方式:血清甘油三酯的酶法测定与基于脂肪酶的血清甘油三酯测定、安培型酶传感器的构建方法学、以及以氧电极为换能基础的生物传感器制备。该组为芯片选定G3PO氧化产生H2O2/O2消耗这一可电学读取的信号通道、以及校准与参考方法(医院生化仪)一致性验证提供原理与标准化参照。相关文献:J. Narang et. al, 2010 等 4 篇文献
共同点聚焦"酶怎样被固定并长期保持活性与级联效率":脂肪酶与甘油激酶的戊二醛共价偶联及多酶共固定化(含可重复使用酶条)、丝素蛋白盐驱动自组装无交联剂多酶共包埋、机械研磨丝素纳米纤维固定化、丝素蛋白作为可吸收生物相容性酶固定基质、丝素水凝胶封装 graphene FET、石墨烯-水凝胶杂化与纳米颗粒平台的理性设计,并配合组织液—水凝胶内底物扩散动力学分析。该组直接支撑本项目"丝素蛋白水凝胶作敏感膜基质+三酶共固定"的选材、级联配比调控、抗蛋白吸附与在体寿命论证。相关文献:N. Chauhan et. al, 2014 等 11 篇文献
共同点提供伴侣动物血脂代谢紊乱的临床痛点与市场需求证据:犬肥胖/超重的患病率与关联因素调查、猫肥胖与高脂血症从发病机制到预防的综述(慢性低度炎症、胰岛素抵抗、继发糖尿病与心肌病)、犬原发性/继发性高脂血症的病因构成与贝扎贝特治疗转归、高脂血症相关疾病与体况/体型指标的相关性、猫继发性高甘油三酯血症的病因与贝特类疗效安全性,以及兽医科诊疗模式变化的时代背景研究。该组支撑"老年犬猫早期无症状、需反复抽血、继发胰腺炎/肾病/糖尿病"的监测缺口与提前干预价值论证。相关文献:Miki Kobayashi et. al, 2025 等 7 篇文献
总计 87 篇相关文献
No abstract available
This paper presents a wireless passive inductor-capacitor (LC) temperature sensor with controllable structural parameters and adjustable frequency. Combining an equivalent circuit model with electromagnetic simulation, the regulation laws of coil turns and dielectric layer thickness on the resonant frequency are quantitatively analyzed. Since the fundamental mechanism of LC frequency tuning is well-understood, the core contribution of this work lies in the specific characterization of the proposed sensor architecture, verifying the feasibility of achieving frequency-on-demand design through geometric optimization. In terms of manufacturing, Zinc (Zn) foil is used as the inductor material, and thermosensitive Polyethylene Glycol (PEG) is utilized as the dielectric layer. The sensor prototype is fabricated using laser micro-machining and lamination processes. Experimental results demonstrate that the sensor exhibits good linearity within the physiological temperature range, with an average sensitivity of 0.6 MHz/°C. Furthermore, it maintains effective wireless signal transmission at a coupling distance of up to 18 mm. This study provides theoretical basis and technical support for the frequency customization and structural design of wireless passive sensors.
This work presents an LC resonant passive wireless gas sensor with a novel structure designed to mitigate the negative impact of substrate. The LC sensor antenna in the new structure, and the reader antenna, were designed and optimized utilizing HFSS software to improve the transfer efficiency. The superiority of the designed structure compared with general examples is highlighted and verified. The change in the substrate capacitance essentially makes no interference with the parameters of the LC sensor to be measured. The sensor for the new structure was prepared by combining etching and sputtering methods. The ZnO nanowires (NWs) were characterized to confirm their high purity and wurtzite crystal structure. The LC gas sensors demonstrated excellent wireless sensing performance, including a low detection limit of 0.5 ppm NO2, high response of 1.051 and outstanding stability at 180 °C. The newly developed sensor structure not only prevented interference from the substrate during gas sensing testing, but also expanded the choice of sensor substrates, playing a critical role in the development of sensors based on the LC resonance principle.
This paper proposes a dual inductor-capacitor (LC) circuit integrated wireless and passive force and temperature sensor for the simultaneous measurement of force and temperature in high-temperature environments. The sensor is fabricated by a two-step process: the preparation of the Al2O3 substrate and the fabrication of the dual LC sensor with Ag paste using screen-printing technology and metallization. The variation in ambient force and temperature can be detected wirelessly by extracting the resonant frequencies of the antenna. The sensor can work in the force range of 0–10 N and temperature range of 25–500 °C with a maximum force sensitivity of 107 kHz/N at 500 °C and temperature sensitivity of 21.7 kHz/°C. To precisely measure the force, the temperature compensation method is proposed. The sensor has the advantages of low cost, simple fabrication and test, and high stability and repeatability, which are promising for the force and temperature application on the engine turbine blade in high-temperature environments.
In this work we present a development of a reusable wireless non-enzyme glucose sensor based on the resonant inductor-capacitor (LC) passive circuit fabricated explicitly on a low-cost FR4 substrate. In our experiments, glucose/water solutions with varying concentrations have been utilized to evaluate the characteristics of the proposed structure. The obtained results showed that the fabricated sensor’s effectiveness in accurately identifying glucose concentrations ranging from 0.1 mM to 100 mM. The sensor’s sensitivities were estimated to be 9.595 MHz/mM, 0.7659 MHz/mM, and 0.2709 MHz/mM for 0.1 to 0.9 mM, 1 to 10 mM, and 10 to 100 mM glucose concentration ranges, respectively. The sensor’s limit of detection (LOD) was calculated to be 0.105 mM for the glucose range from 0.1 to 0.9 mM. In particular, the sensitivity changes most significantly within the glucose concentration range of 0.1 to 0.9 mM, indicating that the sensor is particularly effective at detecting lower glucose concentrations. The obtained characteristics suggest that this sensor is suitable for applications requiring precise measurements of glucose solution.
In this work, a wireless passive LC resonant sensor based on DuPont 951 ceramic is proposed and tested in a developed high-temperature/pressure complex environment. The test results show that the measured resonant frequency varies approximately linearly with the applied pressure; simultaneously, high temperature causes pressure signal drift and changes the response sensitivity. Through the theoretical analysis of the sensor structure model, it is found that the increase in the dielectric constant and the decrease in the Young’s modulus of DuPont 951 ceramic are the main causes that affect the pressure signal in high-temperature measurement. Through calculations, the Young’s modulus of DuPont 951 ceramic is found to decrease rapidly from 120 GPa to 65 GPa within 400 °C. Therefore, the LC resonant pressure sensor needs a temperature compensation structure to eliminate the impact of temperature on pressure measurement. Finally, a temperature compensation structure is proposed and fabricated, and the pressure response after temperature compensation illustrates that temperature drift is significantly reduced compared with that without the temperature compensation structure, which verifies the feasibility the proposed temperature compensation structure.
Wireless passive LC sensors hold significant potential for bearing condition monitoring, however, their development in metallic environments remains constrained by signal attenuation and insufficient sensitivity. This paper presents a novel dual-sensitive LC temperature sensor, featuring a design that incorporates a spiral inductor and parallel-plate structure clamping a polyimide (PI) dielectric material, with a ferrite composite integrated at the bottom to enhance electromagnetic coupling. The sensor leverages the temperature-dependent characteristics of ferrite permeability and the dielectric constant of PI to achieve synergistic tuning of inductance and capacitance, enabling a high-sensitivity temperature response with both parameters exhibiting consistent trends under thermal variation. The integration of ferrite materials significantly enhances magnetic coupling efficiency, effectively suppressing electromagnetic shielding effects in metallic environments, thereby extending the maximum reading distance to 17 mm. Experimental results demonstrate a temperature sensitivity of 139.32 kHz °C−1 within the 40 °C–100 °C range, representing a 3.7-fold improvement over traditional single-sensitive sensors. The sensor exhibits outstanding stability and repeatability under bending, thermal cycling, humidity, and pressure disturbances. This work provides a highly sensitive and reliable solution for real-time temperature monitoring of bearings in metallic enclosures, demonstrating substantial engineering applicability.
This study presents a highly sensitive wireless passive flexible pressure sensor. The sensor employs an ionic film as the dielectric layer, utilizes a spiral coil as the antenna for transmitting and receiving signals of the sensor, and adopts a sandwich process to complete the fabrication of the sensor. This study validates through circuit analysis and simulation that the sensor can be used for wireless passive detection of pressure information. First, the performance of the ionic film is examined. The sensor fabricated with the ionic film has high sensitivity (38.74 N-1), fast response time (100 ms), and high stability. This study also tests the wireless transmission performance between the sensor and the antenna. The test results indicate that the sensor can achieve wireless signal detection within a range of 13 mm. The pressure sensitivity of the sensor in the range of 0–0.5 N is 394.94 MHz/N. When the applied pressure increases from 0.5 to 10 N, the resonant frequency of the sensor decreases from 210 to 160 MHz, and the pressure sensitivity is 4.15 MHz/N. The sensor can realize palm bending detection, breathing, and voice recognition, and has extensive application prospects in the fields of human-computer interaction and wearables.
Aiming at the problem that the sensitivity of LC pressure sensors is restricted due to the use of single inductance or single capacitance sensing mechanisms, the paper proposes a highly sensitive flexible LC pressure sensor based on a dual-sensing mechanism. The anisotropically distributed nano-iron particles doped porous polydimethylsiloxane (PDMS) film and ferrite film are respectively used as the capacitance and inductance sensitive layers of the pressure sensor. The capacitance is affected by the change in dielectric constant of the porous PDMS film under different compression states. The change in distance between the LC resonant circuit and the ferrite film will cause a change in the effective magnetic permeability, hence achieving a controllable response of the inductance in the LC circuit. Based on the dual sensitive mechanism of the cooperative response of inductance and capacitance under pressure, the resonant frequency of the LC sensor can be significantly shifted, thereby breaking through the limitation of improving the sensitivity of the LC pressure sensor. In addition, ferrite films can effectively shield metal signal interference, consequently enhancing the stability and accuracy of wireless detection signal transmission performance. Within the pressure range of 0–10 kPa, the sensitivity of the sensor is 434.64 kHz kPa−1, the signal quality factor is 30, and the maximum hysteresis error and maximum repeatability deviation are less than 0.723% and 0.4 MHz respectively. Through the dual sensitivity mechanism of inductance and capacitance, the sensor achieves highly sensitive pressure detection. Its flexible structure and high sensitivity are particularly suitable for applications such as wearable health monitoring and human–computer interaction, and provide new ideas for the optimized design of flexible LC pressure sensors.
No abstract available
This paper presents a wireless passive spherical capacitive-based resonant sensor for in-situ underground soil moisture monitoring. The sensor features a hollow spherical structure housing a resonant coil and orthogonally arranged capacitive sensing electrodes, forming an LC tank circuit with its resonant frequency shifting in response to soil moisture change. An outer spherical encapsulation provides a lcm clearance around the sensing elements, thus ensuring a high-Q resonance, critical for the wireless operation through soil. The system employs a two-phase inductively coupled operation: in Phase-I, an RF energy is wirelessly transferred to the sensor from above-ground; in Phase-2, the sensor's exponentially decaying response exhibiting a moisture dependent frequency is detected. Laboratory characterization demonstrates a sensitivity of 30fF per 1 % of volumetric moisture change and reliable communication through 15 cm of soil.
In this paper, we report an LC microsystem with the potential for passive wireless measurement of pulmonary artery (PA) pressure, which consists of a micromachined pressure-sensitive capacitor based on a low-resistance silicon substrate (CLRS) or intrinsic silicon substrate (CIS) and a PCB-based planar spiral inductor in parallel. The integrated capacitor, fabricated using MEMS technology, has dimensions of 11*2.6*0.5mm, much smaller than the size of the PA. Despite its compact size, the capacitor has a capacitance of up to about 12pF due to the 1.5μm short cavity gap, while the pull-in effect is effectively avoided during the anodic bonding process by introducing an optimized electrostatic shielding design with local equipotential leads. The resonant frequency of the LC microsystem shifts from 27.38MHz to 26.57MHz at various external pressures of 0-100mmHg, with a sensitivity up to 8.1kHz/mmHg, a nonlinearity of 0.43%, and a Q-factor of more than 10. These results demonstrate the capability of the proposed system for continuous PA pressure monitoring.
Film-based passive wireless temperature sensors have been investigated extensively by many groups over the decades but often require machining to facilitate a series connection between the inductor and capacitor, which make up a particular sensor. In this letter, a fully planar passive wireless near field temperature sensor is presented. The sensor is comprised of Pt and was fabricated using sputter deposition. The operating mechanism for the sensor is a change in the relative permittivity of the dielectric material, which it is deposited on with temperature that results in a reproducible shift in resonant frequency of the sensor. Some sensors were coated with a 1μm layer of HfO2 to enhance the capacitance and protect the underlying Pt from dewetting. The high temperature wireless sensor was demonstrated up to 560°C with high linearity and had a sensitivity of ∼33 KHz/°C while uncoated and ∼25 kHz/°C when the HfO2 coating was present.
Flexible wireless passive inductance–capacitance (LC) pressure sensors exhibit considerable potential in diverse pressure monitoring applications. Nevertheless, their performance has been persistently constrained by the intrinsic trade-off between sensitivity and detection range. In this study, a flexible LC pressure sensor with high sensitivity is presented, employing a dielectric layer engineered with a magnetic field-induced ciliary microstructure this enhanced performance is achieved through the synergistic optimization of microstructural design and the precise modulation of dielectric material properties. The designed dielectric layer introduces a directional magnetic field during the curing process of the PDMS matrix doped with hydroxyl iron powder, simultaneously achieving the chain-like ordered arrangement of hydroxyl iron particles and the controllable construction of polymer cilia microstructures. This magnetically engineered ciliary microstructure breaks the inherent sensitivity-range trade-off through a gradient compression deformation mechanism, enabling both ultrahigh low-pressure sensitivity and a broad linear detection range. The resulting LC sensor exhibits excellent comprehensive performance with a sensitivity of 2824 kHz kPa−1 in the 0–20 kPa range and a stable response of 76.6 kHz kPa−1 in the 20–200 kPa range, successfully balancing high sensitivity and wide range. It also features rapid dynamic response (180 ms 200 ms)−1, an ultra-low detection limit (8 Pa), good cycle stability, and excellent temperature and humidity adaptability. Wireless testing shows that its quality factor Q value can reach 55, demonstrating efficient signal transmission and resonant characteristics. The sensor demonstrates high precision and reliable signal response. The study provides a new approach to solving the inherent trade-off between sensitivity and range of flexible wireless pressure sensors through the collaborative optimization of microstructure design and dielectric materials, laying a technical foundation for their application in wearable health monitoring and interactive devices, and showing promising application prospects.
This article proposes a wireless passive <italic>LC</italic> flexible strain sensor based on a curved-beam interdigital capacitor for large-deformation strain monitoring. The sensor integrates a screen-printed TPU-based capacitive unit with an FPC-fabricated polyimide (PI)-based planar spiral inductor through hot pressing. Among the tested straight-beam and curved-beam structures, the <inline-formula> <tex-math notation="LaTeX">$\textit {k} =0.04$ </tex-math></inline-formula> mm<inline-formula> <tex-math notation="LaTeX">${}^{-{1}}$ </tex-math></inline-formula> sensor shows a higher sensitivity of 353.51 kHz/%, which is about 15.81% higher than that of the straight-beam sensor. Further characterization of this sensor gives a sensitivity of 328.16 kHz/% with <inline-formula> <tex-math notation="LaTeX">$\textit {R}^{{2}} =0.982$ </tex-math></inline-formula> over 0%–40% strain, and a piecewise sensitivity of 432.01 kHz/% over 0%–17.14% strain. The maximum repeatability and hysteresis errors are ±6.53% FS and 6.75% FS, respectively, and no obvious systematic attenuation or drift is observed after 50 loading–unloading cycles. These results indicate that the curved-beam interdigital capacitor structure can improve the frequency response of wireless passive <italic>LC</italic> flexible strain sensors, providing a structural design strategy for large-deformation strain detection.
No abstract available
No abstract available
No abstract available
Wireless passive sensors based on inductor-capacitor (LC) circuits have been an area of intense research in wearable electronics because of their battery-free and wirelessly connected operation. However, significant challenges remain in achieving high sensitivity and long-range performance for such device. In this study, we present a bilayer coils LC wireless passive iontronic pressure sensor (BWIPS) that overcomes these limitations. The bilayer coils strategy enhances the coupling effect and extends the operating distance up to 20 mm. Meanwhile, the capacitive iontronic pressure sensor (IPS) achieves high sensitivity (0.54 kPa−1) and a broad sensing range (400 kPa). By integrating bilayer coils and IPS, the BWIPS exhibits a remarkable sensitivity of −37.4 kHz kPa−1. Furthermore, the flexibility of the sensor allows it to maintain its resonant frequency regardless of various bending radius, making it suitable for use in prosthetic devices. Our BWIPS technology holds great potential for advancing the development of wireless passive sensors in the future, particularly in applications that require high sensitivity, broad sensing range, and non-contact detection at a distance.
The CardioMEMS pulmonary artery (PA) monitoring system placed in the left lower lobe pulmonary artery is capable of measuring pulmonary artery pressure remotely as a surrogate of intracardiac filling pressures and volume status. The technique is safe and reliable. By using remote PA monitoring for proactive medical interventions, there is a growing body of clinical evidence for a substantial, robust reduction in HF hospitalizations in various populations (clinical trial setting, post-marketing studies and real-world experiences). This review summarizes the clinical evidence, outlines future perspectives, and aims for remote patient care in heart failure using CardioMEMS.
Remote haemodynamic monitoring with an implantable pulmonary artery (PA) sensor has been shown to reduce heart failure (HF) hospitalizations and improve quality of life. Cost‐effectiveness analyses studying the value of remote haemodynamic monitoring in a European healthcare system with a contemporary standard care group are lacking.
Heart failure (HF) is increasing in prevalence and is responsible for frequent hospitalization and readmissions, despite current guideline recommended therapies. Hemodynamic guided HF management using frequently remotely obtained pulmonary artery (PA) pressure information using a permanently implanted PA sensor (CardioMEMSTM HF System, Abbott) consistently reduced HF hospitalizations (HFH) in multiple healthcare settings. The safety and efficacy of the CardioMEMS HF System has been shown previously in several clinical studies, which reported significant reductions in HFH compared to a control (CHAMPION: 33%, 18M; GUIDE-HF: 28%, 1 yr; and MONITOR-HF: 44%, 1 yr) and longitudinally (MEMS-HF: 62%, 1 yr; and CardioMEMS US PAS: 57%, 1 yr) across varying health systems. The CardioMEMS HF System OUS Post-Market Study (COAST) aimed to evaluate the safety and effectiveness of hemodynamic guided HF management in patients with NYHA Class III HF in varying health systems across Europe and Australia. COAST is a prospective, multi-centre, open-label clinical trial that consented 321 patients at 38 European and Australian centres. The primary endpoint is a combination of safety (freedom from DSRCs and freedom from pressure sensor failure at 2 years after implant) and efficacy endpoints (annualized HFH rate at 1-year vs the HFH rate in the year prior to enrolment). In this analysis we report these primary results of the study. Out of 321 consented patients, 17 subjects were withdrawn before implant, while the PA sensor was implanted successfully in 299 out of 304 patients who underwent the procedure (98.3% success rate). Seventy-three percent (73%) of the patients were male, the mean age was 68.4±11.7 years with ischemic cardiomyopathy in 45.4%. At baseline, all patients had NYHA Class III symptoms and an average EQ-5D-5L VAS score of 60.0±21.6. After 2 years follow-up there was 100% freedom from DSRCs and 99.7% freedom from pressure sensor failure. The annualized HFH rate after 1 year decreased by 69%, from 1.586 (pre-implant) to 0.488 (post-implant) (p<0.0001). The patient’s quality of life (EQ-5D-5L VAS) increased 8.1 units (68.2 ± 20.1, p=0.0008). The COAST Study demonstrated that hemodynamic-guided remote HF management using PA pressure information is both safe and effective, with consistent implant safety and low risk for long-term sensor failure. At 1 year post implant, HFH were significantly reduced and quality of life improved. These results are also consistent with long-term clinical follow-up (2 yr) in other geographies with no late-stage adverse events or adverse events from sensor implant, demonstrating the generalizability of this type of hemodynamic-guided HF management.
Abstract Aims The aim of this study was to analyse the feasibility, safety, and clinical benefit of the CardioMEMS HF System in different healthcare systems outside the United States of America. Methods and results Prospective, open-label registry of NYHA class III patients with at least one heart failure hospitalization (HFH) within 12 months before enrolment, regardless of left ventricular ejection fraction. The primary safety endpoints assess the freedom from device/system-related complications (DSRC) and freedom from pressure sensor failure (PSF) at 2 years post-implant. The primary efficacy endpoint was the rate of HFH one year before and one year after implantation. Three hundred and four patients from 37 centres in 6 countries underwent a CardioMEMS implant procedure, which was successful in 98.3% of the cases. At 2 years, there were no DSRCs and only 1 PSF. There were 517 HFH in the year before implant compared with 144 HFH in the year post-implant (risk reduction: 69% (RR: 0.31 95% CI [0.25–0.37]; P < 0.0001). Pulmonary artery (PA) pressures were significantly lowered (mean PA pressure reduction: −3.07 ± 5.91 mmHg, P < 0.0001) with a significant improvement in functional class and quality of life (mean EQ-5D-5L visual analogue score increase 8.1 ± 22.7, P < 0.0001). Conclusion The results of the COAST study demonstrate that the CardioMEMS HF System is a reliable device, with no device-related complications and very few pressure sensor failures. Its use is associated with a substantial HFH risk reduction, with a significant reduction in PA pressures, an improvement in NYHA classification, and an improvement in quality of life. Clinical registration number ClinicalTrials.gov Identifier: NCT02954341.
No abstract available
No abstract available
Heart failure (HF) is one of the most important healthcare issues due to its prevalence, high morbidity and mortality, as well as its economic burden. A shift in the healthcare model towards reducing inpatient hospitalizations might have a significant impact on HF-related costs and quality of life. Recently, wireless monitoring has begun to be an essential part of the management in the patient with HF. The CardioMEMS HF system is one of the best examples pertaining to the success in this field. This article will discuss the CardioMEMS HF system and the rationale behind its development.
No abstract available
Heart failure (HF) leads to repeat hospitalisations and reduces the duration and quality of life. Pulmonary artery pressure (PAP)‐guided HF management using the CardioMEMS™ HF system was shown to be safe and reduce HF hospitalisation (HFH) rates in New York Heart Association (NYHA) class III patients. However, these findings have not been replicated in health systems outside the United States. Therefore, the CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF) evaluated the safety, feasibility, and performance of this device in Germany, The Netherlands, and Ireland.
Background Heart failure (HF) is a major cause of hospital readmissions, accounting for substantial morbidity and rising healthcare expenditures. Traditional monitoring strategies rely on patient-reported symptoms and weight changes, which often identify decompensation too late for effective intervention. Project Rationale Pulmonary artery (PA) pressures increase days to weeks before the onset of symptoms, providing an opportunity for more proactive interventions. CardioMEMS implant is a wireless, Food and Drugs Administration-approved device that enables daily remote PA pressure monitoring to guide therapy adjustments and potentially reduce preventable hospitalizations. Project Summary At Wellstar MCG Health, we implemented CardioMEMS monitoring in NYHA functional class III HF patients. Eligible patients underwent minimally invasive PA sensor placement followed by structured provider and patient education. Remote monitoring allowed timely medication adjustments based on pressure trends, which reduced HF readmissions and improved patient-reported quality of life. Take-Home Message CardioMEMS-guided PA pressure monitoring supports proactive HF management, reducing readmissions and enhancing care delivery.
There is a clinical need for additional remote tools to improve left ventricular assist device (LVAD) patient management. The aim of this pilot concept study was to assess the safety and feasibility of optimizing patient management with add‐on remote hemodynamic monitoring using the CardioMEMS in LVAD patients during different treatment stages.
Introduction: Heart failure (HF) in pregnancy is associated with high maternal and neonatal mortality. Remote pulmonary artery pressure (PAP)-guided management of HF has been shown to reduce hospitalizations and mortality in HF patients. However, PAP monitoring systems (CardioMEMS) have not been implanted during pregnancy. We describe the first case of safe implantation of CarioMEMS in a pregnant patient with HF. Case report: A 38-year-old female with past medical history of non-ischemic cardiomyopathy with an ejection fraction of 15%, left ventricular thrombus, pulmonary hypertension, and atrial fibrillation was found to be 14 weeks pregnant by the obstetrician, and her HF medications were appropriately discontinued. The patient was continued on metoprolol, amlodipine, and enoxaparin and was advised to terminate the pregnancy due to high risk of maternal mortality, however, she decided against it. An interdisciplinary team of obstetricians and cardiologists managed the patient during her pregnancy. As the pregnancy progressed, the patient had multiple hospitalizations due to decompensated HF. To optimize her hemodynamic status and guide diuretic therapy, a decision to implant CardioMEMS was made after a risk-benefit discussion, at 23 weeks of gestation. A long wire and sheath were used from a femoral venous access to limit fluoroscopy. A right heart catheterization was performed, and cardiac filling pressures and output were measured. Minimal contrast (7.5 ml of iodixanol) was used to perform selective pulmonary artery angiography and the sensor was implanted according to manufacturer recommendations. Total fluoroscopic exposure during the procedure was 11.2 minutes (183 Gy-cm2). Patient’s diuresis and afterload reduction was adjusted based on PAP. Conclusion: Remote PAP monitoring system can be safely implanted in pregnant patients using limited contrast and fluoroscopic exposure to proactively manage heart failure.
No abstract available
No abstract available
No abstract available
No abstract available
An enhanced amperometric triglyceride (TG) biosensor was created by electrodepositing graphene oxide nanoparticles (GrONPs) onto pencil graphite electrode (PGE) and then co-immobilizing enzyme nanoparticles (ENPs) of lipase, glycerol kinase nanoparticles (GKNPs), and glycerol 3-oxidase (GPONPs), onto this modified electrode. Electrochemical impedance spectroscopy (EIS), cyclic voltammetry, and scanning electron microscopy (SEM) were employed to examine the working electrode (ENPs/GrONPs/PGE) at various phases of its creation. At an applied potential of 0.3V, the biosensor showed its best current response within- 2s. The electrode's ideal pH and temperature were 7.5 and 40˚C, and its linearity was seen for triolein in the concentration range of 0.01 to 60 mM, with a detection limit (LOD) of 0.2 nM. In human serum, the biosensor showed an analytical recovery of 98% for added triolein. The coefficients of variability both within and between batches were 0.048% and 0.05%, respectively. The TG levels in sera as determined by the current biosensor and the conventional enzymic colorimetric technique showed a significant correlation (R2 = 0.99). This biosensor measured the levels of TG in the serum of patients with cardiogenic shock and hyperlipidemia as well as those who appeared to be in apparently healthy condition. The storage stability of electrode revealed only 25% decrease in its initial activity of the electrode, after its regular uses for 240 days of storage in dry condition at 4˚C. Int. J. Appl. Sci. Biotechnol. Vol 13(1): 1-11. Graphical Abstract: Construction of triglyceride biosensor based on LipaseNP/GKNPs/GPONPs/GONS/PGE.
No abstract available
No abstract available
No abstract available
No abstract available
No abstract available
No abstract available
An amperometric enzyme sensor for determination of triglycerides (TGs) was constructed by co-immobilization of lipase (E.C.3.1.1.3), glycerol kinase (GK, E.C.2.7.1.30), and glycerol-3-phosphate oxidase (GPO, E.C.1.1.3.21) on Au/PEDOTPSS nanocomposite modified on screen-printed carbon electrodes (SPEs), then connecting it to potentiostat along with Ag/AgCl reference electrode and Pt auxiliary electrode. In this study, the experiments were divided into two parts. Firstly, the effects of precursor and EDOT concentration of Au/PEDOT-PSS polymerization on electrochemical response were studied. It revealed that Au nanoparticle from precursor enhanced the electrochemical response. Optimal conditions of modified SPEs for TGs detection were fabricated from 0.015 M EDOT and 6.25 mM precursor. Secondly, effects of printed layer of Au/PEDOT-PSS nanocomposite on electrochemical response. It was found that the optimum of printed layer was fabricated at 5 layers.The biosensor measures the electrons generated from H₂O₂ under a potential of 0.4 V which in turn formed from triolein/TGs by co-immobilized lipase, GK and GPO. The concentration of triolein/TG was directly proportional to the current measured. The enzyme electrode showed optimum response when operated at 30±2°C in 0.1 M sodium phosphate buffer, pH 7.0. Linear range of this biosensor was found in the range from 0.1-6.0 mM. The sensitivity of this biosensor was 2.66μA/mM and the detection limit of 0.09 mM triolein was obtained. The response time of this biosensor was found within 30 s. However, the current response of this biosensor decreased to 50% of the initial current after 30 days of storage at 4°C. Moreover, the R.S.D. of this biosensor reproducibility was 9.75%
No abstract available
No abstract available
No abstract available
No abstract available
No abstract available
Background & objectives: Reusable biostrip consisting enzymes immobilized onto alkylamine glass beads affixed on plasticized PVC strip for determination of triglyceride (TG) suffers from high cost of beads and their detachments during washings for reuse, leading to loss of activity. The purpose of this study was to develop a cheaper and stable biostrip for investigation of TG levels in serum. Methods: A reusable enzyme-strip was prepared for TG determination by co-immobilizing lipase, glycerol kinase (GK), glycerol-3-phosphate oxidase (GPO) and peroxidase (HRP) directly onto plasticized polyvinyl chloride (PVC) strip through glutaraldehyde coupling. The method was evaluated by studying its recovery, precision and reusability. Results: The enzyme-strip showed optimum activity at pH 7.0, 35°C and a linear relationship between its activity and triolein concentration in the range 0.1 to 15 mM. The strip was used for determination of serum TG. The detection limit of the method was 0.1 mM. Analytical recovery of added triolein was 96 per cent. Within and between batch coefficients of variation (CV) were 2.2 and 3.7 per cent, respectively. A good correlation (r=0.99) was found between TG values by standard enzymic colrimetric method employing free enzymes and the present method. The strip lost 50 per cent of its initial activity after its 200 uses during the span of 100 days, when stored at 4°C. Interpretation & conclusions: The nitrating acidic treatment of plasticized PVC strip led to glutaraldehyde coupling of four enzymes used for enzymic colourimetric determination of serum TG. The strip provided 200 reuses of enzymes with only 50 per cent loss of its initial activity. The method could be used for preparation of other enzyme strips also.
No abstract available
No abstract available
No abstract available
No abstract available
Background Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs. Objective To assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride (TG) and cholesterol (CHO) concentrations. Animals Forty‐six dogs, 26 females and 20 males, mean (±SD) age of 9 (±3) years, with TG ≥150 mg/dL (33 dogs also were hypercholesterolemic [>300 mg/dL]). Methods Prospective, uncontrolled clinical trial. Dogs were treated with bezafibrate once daily, using 200 mg tablets at a dosage of 4–10 mg/kg (depending on body weight). Serum TG and CHO concentrations and alanine aminotransferase (ALT) and creatine kinase (CK) activity before and after 30 days of treatment were compared. Results Sixteen dogs (34.8%) had primary hyperlipidemia, and 30 dogs (65.2%) had secondary hyperlipidemia (including spontaneous hyperadrenocorticism [41.3%, n = 19/46], chronic treatment with glucocorticoids [10.8%, n = 5/46], and hypothyroidism [15.2%, n = 7/46]). After 30 days, serum TG concentration normalized (<150 mg/dL) in 42 dogs (91.3%) and CHO concentration normalized (<270 mg/dL) in 22 of 33 dogs (66.7%). There was no difference in baseline TG concentration between the primary and secondary hyperlipidemia subgroups, but the decrease in TG concentration after treatment was greater in the primary hyperlipidemia subgroup. No adverse effects were observed, but ALT activity decreased significantly after 30 days of treatment. Conclusions and Clinical Importance Over 30 days, BZF was safe and effective in treatment of primary and secondary hyperlipidemia in dogs.
Canine obesity is associated with comorbidities, a shortened lifespan, and a poorer quality of life, but epidemiological studies characterizing canine obesity in Latin America are scarce. Therefore, this study aimed to determine the prevalence of canine obesity in the city of Sao Paulo, Brazil, and the possible associated causal factors. Randomly-selected households from different city regions were visited. Dogs in each household were evaluated and owners completed a questionnaire whilst their anthropometric measures were taken. Total of 285 dogs from 221 owners were included, and the combined prevalence of overweight and obesity was 40.5%. The prevalence of overweight and obesity was greater in female dogs (P = 0.003) and in dogs that were neutered (P = 0.001). There was also a positive association between BCS and frequency of visits to a veterinarian (P = 0.026), feeding frequency (P = 0.033), and higher snack intake (P = 0.011). Further, the BCS of dogs was greater when their owners reported consuming more snacks themselves (P = 0.005) and whose had a presence of elderly people in the household (P = 0.006). In conclusion, the prevalence of obesity found in a Brazilian metropolitan region was similar to that if other countries, and neutering and snack intake were associated with the development of this disease.
No abstract available
Silk‐fibroin is utilized as a biocompatible and bioresorbable enzyme immobilization matrix and exemplarily demonstrated for a screen‐printed amperometric glucose biosensor. The silk‐fibroin is derived from the silkworm Bombyx mori. The enzyme immobilization matrix consisting of silk‐fibroin, together with glucose oxidase from Aspergillus niger, is applied to a screen‐printed carbon‐based, biocompatible, and biodegradable working electrode on a flexible silk‐fibroin substrate. The biosensor is characterized electrochemically at physiological glucose concentrations in the range from 0.5 to 10 mm. The results are compared to a “conventional” glucose biosensor, also fabricated on a flexible silk‐fibroin substrate, however utilizing a laboratory standard enzyme immobilization matrix based on bovine serum albumin and glutaraldehyde. Furthermore, the influence of pH (pH 5.5 to pH 8.0) and temperature variations (21 to 70 °C) on these two different immobilization matrices are studied.
No abstract available
Azo dyes in textile industry effluents pose significant health and environmental risks. Laccase is an enzyme capable of degrading azo dyes, offering an environmentally friendly solution for treating textile wastewater. However, laccases need to be immobilized on specific carriers to enable effective reuse in batch reactors and continuous operation in flow-through reactors. This study employed silk fibroin nanofibers (SFNFs) obtained by mechanically grinding degummed silkworm silk as sustainable carriers to immobilize laccases through carbodiimide-mediated crosslinking. The immobilized laccases (SFNF-laccases) exhibited improved pH tolerance in the range of pH 3.0-8.0 with a smaller change in activity compared to free laccases (SFNF-laccases: 32.9 %, free laccases: 50.4 %). The thermal stability of immobilized laccases was also improved, showing 19, 13, and 9 % higher activities than those of free laccases at 40, 50, and 60 °C, respectively. After 8 days of storage, the activity of SFNF-laccases was 79 % of their activity immediately after immobilization, whereas free laccases retained only 29 % of their initial activity. In addition, SFNF-laccases maintained 73 % of their original operational activity in a flow-through reactor after 8 days. These results demonstrate the great potential of mechanically ground SFNFs as carriers of laccase and the resulting SFNF-laccases in industrial wastewater treatment.
Injectable hydrogels formed via horseradish peroxidase (HRP)‐catalyzed crosslinking in the presence of hydrogen peroxide (H 2 O 2 ) are promising materials for drug delivery and tissue engineering because of their tunable drug release profiles and mechanical properties. However, the potential immunogenicity of residual HRP poses a major challenge for clinical use. In this study, an HRP‐immobilized mechanically ground silk fibroin nanofiber (SFNF‐HRP) membrane flow‐through reactor was developed to prepare injectable hyaluronic acid (HA) hydrogels with negligible HRP contamination. The reactor enables continuous crosslinking of phenol‐modified HA (HA‐Ph) under physiological conditions. Enzyme‐linked immunosorbent assay (ELISA) signals from the resulting hydrogels were close to the assay's limit of detection (2.01 ng/mL), precluding reliable quantification of residual HRP. The mechanical properties of the hydrogel were readily tuned by varying the linear velocity of the precursor solution, yielding Young's moduli of 0.96–1.7 kPa. The uniform crosslinking density of the hydrogels was confirmed by the consistent Young's modulus observed throughout the 1.5 h continuous preparation. The system also enabled the sustained release of macromolecular model drugs. Release rates could be tuned by controlling the linear velocity during hydrogel preparation, supporting the potential utility of this continuous platform for advanced drug delivery systems.
Silk fibroin self‐assembly is introduced as a fully aqueous, solvent‐ and cross‐linker‐free strategy for noncovalent multienzyme coimmobilization. Salt‐driven structuring enables simultaneous enzyme entrapment within a shared protein matrix, while modulation of ionic strength allows controlled enzyme incorporation and adjustment of cascade stoichiometry. Using the alanine dehydrogenase/formate dehydrogenase redox cascade for l ‐norvaline synthesis as a model system, co‐entrapment within the fibroin matrix enhances operational robustness, sustaining 200 h of cumulative batch operation and achieving a cumulative catalytic turnover exceeding 9000 mol l ‐norvaline per mol of alanine dehydrogenase under the tested conditions. Structural characterization reveals an interconnected microglobular architecture consistent with a confined protein‐based microenvironment capable of influencing diffusion–reaction coupling. Competitive assays indicate reduced NADH accessibility in the coassembled system, consistent with partial cofactor confinement. Extension to additional reductase/glucose dehydrogenase cascades demonstrates compatibility across distinct enzyme classes and reveals substrate‐dependent effects linked to diffusion dynamics and matrix–substrate interactions. Collectively, these results establish salt‐assembled silk fibroin as an active protein matrix that stabilizes multienzyme systems while modulating cofactor accessibility and substrate distribution without covalent modification.
No abstract available
This paper presents a biocompatible antenna for a subcutaneous implantable biosensor. With the large number of Americans who manage chronic diseases, biosensors offer the capability for better management of these diseases. For diabetes, particularly, the most common monitoring system used is a blood finger pricking system only offers snapshots of blood glucose levels and not trends of glucose changes. These limitations yield a demand for a monitoring system that can provide continuous data streams of glucose levels for better dietary and medicinal regimens. Fully implantable systems offer continuous monitoring while not sacrificing normal daily activities that implantable sensors with an external transmitter can pose. One bottleneck is the miniaturization of telecommunication system. Current implantable devices use the MedRadio band, which offer a challenge for antenna miniaturization for subcutaneous implantation. Additionally the use of copper as the radiator is a challenge due to biocompatibility. As a result there is a need for an implantable antenna that utilizes biocompatible materials, such as Titanium Nitrite (TiN). This paper presents the design and fabrication of a TiN antenna for subcutaneous implant operating in the 2.4 GHz ISM band. The simulation and in vivo test data are presented.
No abstract available
Continuous glucose monitoring (CGM) is essential for diabetes management. Optical CGM provides a promising approach, yet current existing optical platforms face challenges including phototoxic excitation, shallow tissue penetration, and limited hardware compatibility. Here, we report a visible-light activated implantable nanophotonic biosensor that enables long-term in vivo glucose tracking through dual spectral and biochemical engineering. The sensor leverages Q-band of metalloporphyrins, shifting excitation from the phototoxic near-UV/blue B-band to the safer visible-light region, and couples with a rhodamine via Förster resonance energy transfer (FRET) to achieve efficient photon harvesting, ratiometric calibration, and CMOS-compatible optical readout. To stabilize enzymatic performance and mitigate oxidative damage, a glucose oxidase/catalase (GOx/CAT) cascade rapidly decomposes hydrogen peroxide (H2O2) byproducts, preserving sensitivity during extended implantation. This integrated design yields a biocompatible, optically compatible, and long-term stable nanophotonic sensing platform, advancing the development of smart terminal-integrated CGM systems with robust in vivo performance and strong translational potential for personalized diabetes management.
Introduction Optimal glycaemic control is crucial during pregnancy in women with type 1 diabetes mellitus (T1D). Current guidelines, based on positive data from the CONCEPTT (Continuous Glucose Monitoring in Pregnant Women With Type 1 Diabetes Trial), on maternal glycaemic control and fetal outcomes, recommend offering real-time Continuous Glucose Monitoring (rt-CGM) as a standard method in all pregnancies of women with type 1 diabetes (T1D). Case Presentation In these two clinical cases, we describe for the first time the gestational outcomes in two patients with T1D who chose to maintain a long-term implantable subcutaneous sensor (Eversense XL®) as a CGM method during their pregnancies. The first case concerns a 33-year-old young woman with a 25-year history of T1D on Continuous Subcutaneous Insulin Infusion (CSII), who faced her first pregnancy with a suboptimal preconception glycaemic control; the second case describes the second pregnancy of a 37-year-old patient with a more recently diagnosed T1D, on multiple daily injection (MDI) therapy who achieved adequate glycaemic compensation before planned conception. Conclusion The subcutaneous sensor replacement was carried out at the beginning and end of the 2nd trimester, respectively, without any complications, allowing optimal monitoring and adjustment of insulin dose and achieving optimal glucose targets throughout the pregnancy until delivery.
Continuous glucose monitoring systems (CGMS) are becoming increasingly popular in diabetes management compared to conventional methods of self-blood glucose monitoring systems. They help understanding physiological responses towards nutrition intake, physical activities in everyday life and glucose control. CGMS available in market are of two types based on their working principle. Needle type systems with few weeks lifespan (e.g., enzyme-based Freestyle Libre) and implant type system (e.g., fluorescence-based Senseonics) with few months of lifespan are commercially available. An alternate to both working methods, herein, we propose electromagnetic-based sensor that can be subcutaneously implanted and capable of tracking minute changes in dielectric permittivity owing to changes in blood glucose level (BGL). Proof-of-concept of proposed electromagnetic-based implant sensor has been validated in intravenous glucose tolerance test (IVGTT) conducted on swine and beagle in a controlled environment. Sensor interface modules, mobile applications, and glucose mapping algorithms are also developed for continuous measurement in a freely moving beagle during oral glucose tolerance test (OGTT). The results of the short-term (1 h, IVGTT) and long-term (52 h, OGTT) test are summarized in this work. A close trend is observed between sensor frequency and BGL during GTT experiments on both animal species.
AIMS OF THE STUDY The Eversense® CGM System is the first and only continuous glucose monitoring system (CGMS) that uses a fully subcutaneous implanted sensor. This study aimed to evaluate effectiveness, safety and patient-reported outcomes in patients using the Eversense® CGM System in a realistic clinical setting, assessed at a single Swiss diabetes centre (Luzerner Kantonsspital) with prolonged follow-up. METHODS This was a prospective and retrospective observational study that included patients with type 1 diabetes mellitus in whom at least one Eversense® glucose sensor was implanted between 2017 and 2022. The primary endpoint was the change in HbA1c levels from the baseline (before implantation of the sensor) to 6 ± 2 and 12 ± 2 months and the last follow-up (newest available value) after implantation. The secondary outcome measures were the number of premature sensor breakdowns, adverse events related to the implantation procedure (infection, bleeding, difficulties with implantation or explantation) and patient-related outcomes (assessed with a questionnaire). RESULTS A total of 33 patients participated in this study. The median follow-up time was 50 (IQR 22.3-58.5) months. In total, 178 sensor implantations were performed. Valid HbA1c results were available for 26 participants. Compared to the baseline values, HbA1c levels at 6 and 12 months and the last follow-up changed by -0.25%, -0.45 and -0.2 (p = 0.278, 0.308 and 0.296, respectively). We recorded 16 (9%) premature sensor breakdowns, all occurring between 2019 and 2020. Apart from one late-onset infection and four complicated sensor removals, no major complications were assessed. The results of the questionnaire showed a subjective improvement in hypoglycaemia rates, a better perception of hypoglycaemia and the impression of better diabetes management. Common issues with the device reported by the patients were technical errors (connection problems) and problems with the removal procedure. CONCLUSIONS The use of the Eversense® CGM System resulted in changes in HbA1c of between -0.2% and -0.45%. The rate of premature sensor breakdown was low. Major complications following sensor implantation or removal were absent, apart from one case of infection and four cases of complicated removal. Patient-reported outcomes with the Eversense® CGM System showed a subjective positive impact on hypoglycaemia rates, greater confidence in managing hypoglycaemia and diabetes in general, and easy handling of the transmitter and mobile app. Technical issues must be considered but are nowadays, with the use of the newest sensor generation, very rare.
Monitoring multiplexed biochemical markers is beneficial for the comprehensive evaluation of diabetes-associated complications. Techniques for multiplexed analyses in interstitial fluids have often been restricted by the difficulties of electrode materials in accurately detecting chemicals in complex subcutaneous spaces. In particular, the signal stability of enzyme-based sensing electrodes often inevitably decreases due to enzyme degradation or interference in vivo. In this study, we developed a self-calibrating multiplexed microneedle (MN) electrode array (SC-MMNEA) capable of continuous, real-time monitoring of multiple types of bioanalytes (glucose, cholesterol, uric acid, lactate, reactive oxygen species [ROSs], Na+, K+, Ca2+, and pH) in the subcutaneous space. Each type of analyte was detected by a discrete MN electrode assembled in an integrated array with single-MN resolution. Moreover, this device utilized an MN-delivery-mediated self-calibration technique to address the inherent problem of decreased accuracy of implantable electrodes caused by long-term tissue variation and enzyme degradation, and this technique might increase the reliability of the MN sensors. Our results indicated that SC-MMNEA could provide real-time monitoring of multiplexed analyte concentrations in a rat model with good accuracy, especially after self-calibration. SC-MMNEA has the advantages of in situ and minimally invasive monitoring of physiological states and the potential to promote wearable devices for long-term monitoring of chemical species in vivo.
Microgel-based in vivo biosensor is an innovative technological concept that focuses on creating nano- and/or micro-scale sensors for health monitoring. Microgel-based sensor (MBS) enables highly sensitive detection of a phenomenon-of-interest through electromagnetic characteristics. This paper presents a novel MBS for implantable health monitoring, and the research contributions can be summarized into two main aspects. Firstly, a novel synthesis method for microgel nanoparticles designed for blood glucose detection is proposed, and a new MBS sensitive to the in vivo microenvironment conditions is successfully synthesized. Comprehensive material characterization is conducted, including analyzing the material’s performance in different blood glucose environments and its temporal variations. Secondly, for this material, its dielectric constant is detected to respond to physiological signals in the human body. MBS is employed as in vivo sensors, converting biological signals within the body into morphological changes of microgel particles (i.e., switching between expansion and contraction forms). Through dielectric constant probes, we detect the dielectric properties of MBS for sensing applications, providing crucial insights for potential biomedical uses of microgels. To discuss the response of the proposed MBS to changes in blood glucose, we consider scenarios of high and low blood sugar. At 2 GHz, it is observed that the dielectric constant is 60.27 during low blood sugar and 20.13 during high blood sugar. These results indicate a high sensitivity of MBS to changes in blood glucose levels.
Continuous glucose monitoring (CGM) is a commercially available biochemical sensor for diabetes management. A growing trend in this field is the transition from long needles to microneedles to reduce pain and avoid bleeding. A promising strategy for microneedle‐based CGM involves using hydrogel as a filler to bridge the interstitial fluid and externally deployed glucose sensors on the skin surface. However, the glucose diffusion dynamics, critical to the sensing process, remain poorly understood. In this study, we investigate the dynamics of glucose diffusion between subcutaneous tissue and hydrogel‐filled microneedles. Specifically, we examine how hydrogel thickness, microneedle size, and glucose concentration influence diffusion. This study provides an experimental reference to the wearable biosensor community researching microneedle‐based CGM.
Abstract In this study, we have explored the potentiality of using GOx/AuNP/PEDOT(BSA)/Pt electrode as an implantable, long-lasting, and sensitive glucose biosensor. We have examined the performance of the electrode for glucose calibration with three electrochemical measurements, such as cyclic voltammetry, linear sweep voltammetry, as well as chronoamperometry, which all exhibited strong linear correlation between resulting signal and glucose concentration. In comparison, linear sweep voltammetry gave the best linear sensitivity, whose average was about 3.124 µA/mM/cm2 within a wide glucose concentration range from 0.416 to 50 mM. Meanwhile, the stability of the electrode was confirmed by a continuous glucose measurement in a 7-day period of time and the deviation was about 5%. The electrode was also biocompatibility according to the ISO109930-1 criterion. Furthermore, we have demonstrated that the oxidation of glucose on the GOx/AuNP/PEDOT(BSA)/Pt electrode was oxygen independent, therefore, it was not only easy to make but also feasible for continuous glucose monitoring systems.
Diabetes mellitus is a chronic illness in the United States affecting nearly 120 million adults, as well as increasing in children under the age of 18. Diabetes was also the 7th leading cause of death in the United States with 270 K deaths in 2017. Diabetes is best managed by tight glycemic control, as achieving near-normal glucose levels is key to reduce the risk of microvascular complications. Currently, continuous glucose monitoring (CGM) systems have been recognized as the ideal monitoring systems for glycemic control of diabetic patients. Briefly, a CGM system measures blood glucose levels in subcutaneous tissue by attaching a CGM sensor to the skin, allowing the users to make appropriate modifications to their medical interventions according to experience or empirically derived algorithms. The principles of the glucose sensing employed in the current commercially available CGM systems are mainly electrochemical, and employ the gold standard enzyme, glucose oxidase, as the glucose sensing molecule with the combination of hydrogen peroxide monitoring or with the combination of redox mediator harboring hydrogel. Recently, by employing an abiotic synthetic receptor harboring a fluorescent probe combined with a fluorescent detection system, a chronic CGM was commercialized. In addition, the development of less or non-invasive monitoring sensors targeting glucose in tears, sweat, saliva and urine have become of great interest although their clinical relevancy is still controversial. This review article introduces current and future technological aspects of CGM systems, the flagship technology in biosensor research, which was initiated, matured and is still growing in North America.
Continuous glucose monitoring (CGM) systems have revolutionized the treatment and monitoring of diabetes. These devices are recommended for diabetic patients treated with insulin, especially with recurring episodes of hypoglycemia or large circadian variation of glucose levels. CGM allows more effective adjustment of insulin doses to blood glucose trends, resulting in better metabolic control: more time spend in glucose target range, lower time spend in hypoglycemic range, lower glucose variability and improved quality of life of patients and their family members. Real time CGM provides patients not only with continuous information on glucose levels but also alerts for hypo- or hyperglycemic events. Traditional transcutaneous CGM have some limitations, which can be resolved by the system with an implantable sensor. The Eversense CGM is the only long-term implantable rtCGM. The subcutaneous implantation procedure has proved to be simple and uncomplicated. This CGM system can be recommended in particular for patients who, due to their profession and sports discipline, cannot or do not want to use traditional transcutaneous sensors. Further groups are patients with skin complications associated with the use of traditional sensors, people who perceive frequent sensor replacement as a burden or would benefit from on-body vibration alerts. The studies showed that the patients were satisfied with Eversense, and the majority used it several times after the study ended. The main reason for resigning from the next implantation was cost of the device.
No abstract available
The article published by Kevin Cowart in this issue of the Journal of Diabetes Science and Technology (JDST) is a detailed overview of the clinical trial data and analysis used to demonstrate the safety and effectiveness of the Eversense continuous glucose monitoring (CGM) System for regulatory approval and clinical acceptance. The article describes the published study results for safety, accuracy, reliability, ease of insertion/removal, adverse events, and ease of diabetes patient-use for controlling their glucose levels short and long term. The author nicely compares Eversense CGM System safety and performance with the short-term subcutaneous tissue CGM systems being commercialized by Dexcom, Medtronic Diabetes, and Abbott Diabetes. This comparison may help the clinician define which type of patient with diabetes might benefit the most from the long-term implantable CGM system. The majority of studied patients describe a positive experience managing their diabetes with the Eversense CGM System and request implantation of a new sensor 90 or 180 days later.
Remote and continuous blood glucose monitoring is a highly researched topic due to the prevalence of diabetes. In addition to being the 7th leading cause of death, diabetes features high comorbidity rates involving chronic diseases such as cardiovascular disease and kidney disease. This is in part due to poor monitoring of blood glucose levels, especially amongst the medically underserved who lack regular physician access. Optical signal transduction via a fully implantable biosensor is a promising way to provide necessary disease monitoring due to potential for low cost, longer lifetime and lack of transcutaneous components. Such a sensor would enable administration through a syringe and thus allow other healthcare workers to administer the biosensor- expanding access. However, light transport through turbid media such as skin features many absorptive and scattering events that lower assay efficacy. One such way to increase signal is the inclusion of multiple sensing modalities and rational design selection. Here, we present design selection for a multimodal and fully implantable glucose biosensor. First, three designs are postulated, then their fluorescence is simulated via Monte Carlo Modeling. The best performing design is then further improved upon by determining the number of needed repeating units as well as length. Overall, it was determined that a stacked cylinder design, 0.43cm in length with 0.036cm thick repeating units provides the best fluorescent signal. Future work should involve the experimental validation of this model, as well as the inclusion of the sensing modalities so that an exact response can be estimated.
No abstract available
Oscillators under inductive resonant coupling are used to reduce phase noise in frequency generation and can also be applied to implement sensor systems. Here the operation of two inductively locked oscillators at an integer frequency ratio is analysed in depth, paying attention to the locking mechanism and identifying the various kinds of steady state solutions. The injection-locked solution curve versus the parameter used for control or sensing is obtained through harmonic balance with the aid of auxiliary generators. When increasing the coupling effects, the locked-operation interval undergoes a significant shift versus the parameter, which is understood with the aid of an analytical formulation. The stability properties and phase noise are analysed by linearizing the system about the mutually injection-locked steady-state solution, through the extraction of an outer-tier Jacobian matrix. The results are validated with time-domain maps based on maxima detection and with measurements.
This article proposes a low-cost and portable device that enables automated detection of microplastic (MP) by using a high-precision 1.1–1.15-GHz radio frequency (RF) micro-electro-mechanical system (MEMS) sensor driver/readout system-on-chip (SoC). The proposed driver and readout SoC operate as an RF signal generator and a spectrum analyzer, respectively, enabling the analysis of resonant frequency shifts corresponding to MP concentration. The driver SoC uses closed-loop power amplifier (PA) envelope regulation (CPA-ER) to maintain consistent output power against frequency shifts. The driver SoC exhibits an output power up to 0.23 dBm at 1.14 GHz and achieves a small output power variation of less than 4.9% between 1.1 and 1.15 GHz. The proposed readout SoC can detect a minimum input power of −10 dBm while achieving a dynamic range (DR) of 18 dB and a low linearity error of 1%. The 180-nm CMOS driver SoC and 250-nm CMOS readout SoC occupy a silicon area of 7.1 and 3.8 mm2, respectively. Upon injecting $5~{\mu }$ L of 1% regular standard polyethylene (PE) dispersion into the RF MEMS sensor five times, the resonant frequency shifts up to 10 MHz. Also, when $5~{\mu }$ L of 1% amorphous polypropylene (PP) dispersion is injected 16 times, the resonant frequency shifts by 14 MHz, verifying that the proposed system can detect MP consisting of PE and PP.
This paper presents a high-precision RF MEMS sensor driver and readout SoC to implement a low-cost portable device for microplastic (MP) detection. The proposed sensor driver and readout SoC operate as a miniaturized RF signal generator and network analyzer, respectively, that can analyze the resonant frequency shift depending on MP concentration. The system also adopts the closed-loop power amplifier (PA) envelope regulation to ensure consistent sensor driving against frequency shift. The 180-nm CMOS sensor driver chip exhibits an output power up to 0.23 dBm at 1.14 GHz and achieves small output power variation of4.9% between 1.1 GHz and 1.15 GHz, compared to 12.6% of the conventional drivers, thanks to PA envelope regulation. The 250-nm CMOS readout SoC can sense a minimum -10dBm input power and detect the changes of the input power with the dynamic range of18 dB, achieving a small linearity error of 1%.
This article presents an enhanced-frequency-splitting-based wireless power and data transfer (EFS-WPDT) system that simultaneously delivers power and forward data over a compact inductive link. For data transmission, the proposed system employs frequency-shift keying (FSK) based on frequency-splitting enhancement (FSE), which is enabled by dynamic link-load isolation (LLI) and time-interleaved $LC$ resonance. This approach effectively addresses the conventional tradeoffs among power delivered to the load (PDL), data rate (DR), and power transfer efficiency (PTE). The dynamic LLI decouples the load during each resonance phase, which is critical for enabling FSE, and is implemented using a quasi-resonant boost converter (QRBC) that provides a boosted and regulated output voltage. For time-interleaved operation, reliable peak detection is achieved by a body-tuned peak detector (BTPD), which maintains accurate timing across varying link conditions. A frequency-to-amplitude converter enhances sensitivity by amplifying envelope differences, enabling robust data demodulation even in the miniaturized link. The presented ICs, fabricated in a 180-nm bipolar-CMOS-DMOS (BCD) process, simultaneously achieve 60.2% overall PTE, 43.4-mW PDL, and 1-Mb/s DR with a sub-centimeter receiver (RX) coil. As a result, the figure of merit (FoM) for data transmission is improved to a level comparable to previous works using centimeter-scale links, while the FoM for power delivery is improved by $2.5\times $ compared to prior state-of-the-art systems, employing a single inductive link.
This article proposes a fast and accurate front-end monitoring method to estimate the coupling coefficient and receiver resonant frequency of wireless power transfer (WPT) systems. The proposed method is developed for universal WPT systems with a series-compensated transmitter. The receiver parameters can be unknown and different from those on the transmitter side. This method is applicable to a range of receivers with first- or second-order compensation (i.e., series, parallel, and none-compensation). It can be extended to the systems with magnetic shielding, and has a strong immunity to the harmonics. Furthermore, a hardware-based identification approach is proposed for receiver compensation without any additional cost. The detection algorithms are analyzed in detail. The proposed scheme requires one additional phase detection sensor of the transmitter current. The zero-phase-angle frequencies of the WPT systems can be determined by fast frequency-sweeping processes with the receiver's active rectifier kept momentarily either short-circuited or open-circuited. Experimental results have been obtained to verify the proposed method, which can accurately estimate both coupling coefficients and receiver resonant frequencies within 2.5–8 ms.
Objectives The aim of this study was to assess the short-term safety and efficacy of fenofibrate in controlling secondary hypertriglyceridemia in cats. Methods This was a prospective cohort study. Seventeen adult cats with hypertriglyceridemia (serum triglycerides [TG] >160 mg/dl) were enrolled. Cats received a median dose of 5 mg/kg (range 3.2–6) fenofibrate (q24h PO) for 1 month. Serum TG, total cholesterol (TC), creatine kinase and liver enzymes (alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase) were evaluated before (t0) and after 1 month (t1) of fenofibrate treatment. Results The causes of secondary hypertriglyceridemia were diabetes mellitus (DM; 29.4%), obesity (29.4%), hyperadrenocorticism (HAC) and DM (11.7%), HAC without DM (5.9%), hypersomatotropism (HST) and DM (5.9%), hypothyroidism (5.9%), long-term treatment with glucocorticoids (5.9%) and chylothorax (5.9%). Serum TG (t0 median 920 mg/dl [range 237–1780]; t1 median 51 mg/dl [range 21–1001]; P = 0.0002) and TC (t0 median 278 mg/dl [range 103–502]; t1 median 156 mg/dl [range 66–244]; P = 0.0001) concentrations showed a significant decrease after 1 month of fenofibrate treatment. Fifteen cats normalized their TG concentration at t1 (88.2%). Of the eight cats that were hypercholesterolemic at t0, six (75%) normalized their TC concentrations at t1. One of 17 cats (5.9 %) presented with diarrhea; the remaining 16 did not show any adverse effects. Conclusions and relevance DM and obesity are the most common endocrine causes of secondary hyperlipidemia, although it can also be found in cats with HAC, HST or hypothyroidism. This study suggests that fenofibrate treatment was associated with reduction and normalization of TG and TC concentrations in cats with moderate and severe hypertriglyceridemia, regardless of the cause of secondary hypertriglyceridemia. Further work should focus on controlled studies with a greater number of cases.
Introduction The global increase in the prevalence of overweight and obesity is associated with several chronic diseases. Obesity is characterized by systemic low-grade inflammation and oxidative stress caused by excessive fat accumulation. This study aimed to establish diagnostic criteria for pathological obesity in cats using a highly sensitive serum amyloid A (SAA) assay. Methods In this study, 29 client-owned cats (3–14 years old) with varying body condition scores (BCS) were included. These cats underwent medical checkups and were not treated for any specific diseases. They were divided into three groups: healthy control, simple obesity, and obesity disease. The plasma levels of metabolites, hormones, and enzymes were measured. Results In the simple obesity cats, body weight, BCS, and plasma triglyceride (TG) and malondialdehyde (MDA) concentrations were significantly higher than those in the healthy control cats. In the obesity disease cats, BCS was significantly higher than that in the simple obesity cats, and plasma TG and SAA concentrations and alanine aminotransferase (ALT) activities increased significantly compared to those in the simple obesity cats. Adiponectin concentrations in the obesity disease cats were significantly lower than those in the healthy control cats. Discussion The novel criteria for feline obesity (overweight cats exhibiting two or more of the following symptoms: hyperlipidemia and high ALT and SAA levels) were based on biomarker values that were significantly higher than those in the simple obesity cats. These novel criteria may help detect pathological obesity at an early stage. Early and accurate diagnosis can prevent age-related diseases including obesity.
There are some limitations to using the body condition score (BCS) for client education to prevent obesity, hyperlipidemia-related diseases, and orthopedic diseases in dogs because it is hard to quantify in detail. Especially in small dogs, patellar luxation is a common orthopedic disease that is related to obesity and the hind leg muscle. In this pilot study, the author evaluated the thorax/thigh circumference ratio as a prognostic evaluation index, along with the BCS, for assessing patellar dislocation and other hyperlipidemia-related diseases and states such as hypertriglyceridemia and obesity-related orthopedic disease in small dogs. Eleven client-owned dogs were selected randomly among patients that visited Bundang New York Animal Hospital, South Korea from June 2021 to August 2024. According to the results, triglycerides (TG) showed a negative correlation with thorax/thigh value (R = −0.585, p-value = 0.059) and a strong positive correlation with thigh circumference (R = 0.749, p-value = 0.008). Total cholesterol (TC) showed a strong positive correlation with thigh circumference (R = 0.776, p-value = 0.005), whereas the thorax/thigh value showed a negative correlation with the medial patella luxation (MPL) grade with low significance (R = −0.343, p-value = 0.302). These data indicate that thigh circumference can be an excellent negative indicator for hyperlipidemia and thorax/thigh value shows no correlation with medial patella luxation, which has many factors such as varus and trochlear groove. Despite the limitations of this study due to the small sample size, this pilot study is significant as it is the first trial to introduce a new indicator for monitoring hyperlipidemia at home by using a simple tape measure. Also, the author reviews molecular pathways including the ApoA-1, ApoE, and LPL genes, which are related to hyperlipidemia, to explain the results.
Overweight and obesity represent the most common nutritional disorder in domestic cats and constitute a significant global health issue. In this review, we synthesize current knowledge on the determinants, diagnosis, pathophysiology, complications, and comprehensive management of feline obesity. Feline overweight and obesity have a complex and multifactorial pathogenesis, arising from an interplay of intrinsic factors (e.g., genetic predisposition, age, sex, neutering status) and extrinsic factors (e.g., environment, owner behavior). The condition is characterized by a state of chronic low-grade systemic inflammation, endocrine dysregulation, insulin resistance, and hyperlipidemia, which collectively elevate the risk of numerous comorbidities, including diabetes mellitus, osteoarthritis, urinary tract disorders, dermatopathies, cardiomyopathy, and respiratory diseases, ultimately compromising life expectancy. This means that early detection and examination of excess body weight are crucial to treatment and prevention; at the same time, weight loss should be centered around personalized nutritional intervention, combined with behavioral correction measures such as regular feeding schedules and increased physical exercise. Furthermore, maintaining good communication between clinicians and the pet owners, as well as continuous monitoring, is the key to achieving effective weight loss. Future research is needed to move beyond current reactive models and embrace a focus on metabolic health over weight, prediction over reaction, and pathogenesis over symptomatology, aiming for preemptive strategies that improve feline healthspan.